X0202 4 2005-05-11 0 0001115285 EYETECH PHARMACEUTICALS INC EYET 0001097962 WICKER DAMION E MD C/O JP MORGAN PARTNERS 1221 AVENUE OF THE AMERICAS 40TH FLOOR NEW YORK NY 10020 1 0 0 0 Common Stock 2240896 I See footnote Director Stock Option (right to buy) 1.44 2002-12-03 2012-12-03 Common Stock 30000 30000 D Director Stock Option (right to buy) 34.34 2014-05-12 Common Stock 10000 10000 D Director Stock Option (right to buy) 23.31 2005-05-11 4 A 0 25000 0 A 2015-05-10 Common Stock 25000 25000 D The amounts shown represent the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners (BHCA), L.P. ("JPM BHCA"), a portion of which may be deemed attributable to the Reporting Person because the Reporting Person is a Managing Director of JPMP Capital Corp., the general partner of JPMP Master Fund Manager ("MF Manager"), the general partner of JPM BHCA. The actual pro rata portion of such beneficial ownership that may be deemed attributable to the Reporting Person is not readily determinable because it is subject to several variables, including the internal rate of return and vesting within JPM BHCA and within MF Manager. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. These options were granted to the Reporting Person as Director's Compensation, the Reporting Person is obligated to transfer any shares issued under the stock option to JPM BHCA. These options became exercisable on June 12, 2004. They will vest in 48 monthly installments. These options will become exercisable on June 11, 2005. They will vest in 48 monthly installments. /s/ Damion E. Wicker 2005-05-13